Phage Pharmaceuticals (Formerly Known as Phage Biotechnology Corp.) to File Investigational New Drug (IND) Application Using Its Lead Drug Candidate, FGF-1, for a First-in-Class Indication to Repair Tympanic Membrane Perforations

SAN DIEGO--(BUSINESS WIRE)--Phage Pharmaceuticals, a private biopharmaceutical company based in San Diego, California, announced today the submission of an IND to the US FDA to initiate a Phase 1 clinical trial of its FGF-1 drug for the repair of tympanic membrane perforations.